Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1947 1
1966 1
1970 1
1974 1
1977 1
1978 1
1979 1
1981 1
1982 3
1983 3
1984 2
1985 4
1986 1
1987 6
1988 10
1989 10
1990 12
1991 10
1992 4
1993 9
1994 5
1995 10
1996 2
1997 13
1998 13
1999 14
2000 8
2001 7
2002 10
2003 26
2004 14
2005 18
2006 15
2007 18
2008 14
2009 10
2010 19
2011 24
2012 13
2013 21
2014 32
2015 20
2016 27
2017 18
2018 23
2019 24
2020 24
2021 22
2022 26
2023 27
2024 22

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

547 results

Results by year

Filters applied: . Clear all
Page 1
Pembrolizumab for Early Triple-Negative Breast Cancer.
Schmid P, Cortes J, Pusztai L, McArthur H, Kümmel S, Bergh J, Denkert C, Park YH, Hui R, Harbeck N, Takahashi M, Foukakis T, Fasching PA, Cardoso F, Untch M, Jia L, Karantza V, Zhao J, Aktan G, Dent R, O'Shaughnessy J; KEYNOTE-522 Investigators. Schmid P, et al. N Engl J Med. 2020 Feb 27;382(9):810-821. doi: 10.1056/NEJMoa1910549. N Engl J Med. 2020. PMID: 32101663 Clinical Trial.
Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial.
Bidard FC, Kaklamani VG, Neven P, Streich G, Montero AJ, Forget F, Mouret-Reynier MA, Sohn JH, Taylor D, Harnden KK, Khong H, Kocsis J, Dalenc F, Dillon PM, Babu S, Waters S, Deleu I, García Sáenz JA, Bria E, Cazzaniga M, Lu J, Aftimos P, Cortés J, Liu S, Tonini G, Laurent D, Habboubi N, Conlan MG, Bardia A. Bidard FC, et al. Among authors: dillon pm. J Clin Oncol. 2022 Oct 1;40(28):3246-3256. doi: 10.1200/JCO.22.00338. Epub 2022 May 18. J Clin Oncol. 2022. PMID: 35584336 Free PMC article. Clinical Trial.
Reducing Unnecessary Oophorectomies for Benign Ovarian Neoplasms in Pediatric Patients.
Minneci PC, Bergus KC, Lutz C, Aldrink J, Bence C, Breech L, Dillon PA, Downard C, Ehrlich PF, Fallat M, Fraser JD, Grabowski J, Helmrath M, Hertweck P, Hewitt G, Hirschl RB, Kabre R, Lal DR, Landman M, Leys C, Mak G, Markel T, Pressey J, Raiji M, Rymeski B, Saito J, Sato TT, St Peter SD, Cooper J, Deans K; Midwest Pediatric Surgery Consortium. Minneci PC, et al. Among authors: dillon pa. JAMA. 2023 Oct 3;330(13):1247-1254. doi: 10.1001/jama.2023.17183. JAMA. 2023. PMID: 37787794 Free PMC article. Clinical Trial.
Substance Use Disorders in Women.
Polak K, Haug NA, Dillon P, Svikis DS. Polak K, et al. Among authors: dillon p. Psychiatr Clin North Am. 2023 Sep;46(3):487-503. doi: 10.1016/j.psc.2023.04.006. Epub 2023 Jun 4. Psychiatr Clin North Am. 2023. PMID: 37500246 Review.
Replicative Instability Drives Cancer Progression.
Morris BB, Smith JP, Zhang Q, Jiang Z, Hampton OA, Churchman ML, Arnold SM, Owen DH, Gray JE, Dillon PM, Soliman HH, Stover DG, Colman H, Chakravarti A, Shain KH, Silva AS, Villano JL, Vogelbaum MA, Borges VF, Akerley WL, Gentzler RD, Hall RD, Matsen CB, Ulrich CM, Post AR, Nix DA, Singer EA, Larner JM, Stukenberg PT, Jones DR, Mayo MW. Morris BB, et al. Among authors: dillon pm. Biomolecules. 2022 Oct 26;12(11):1570. doi: 10.3390/biom12111570. Biomolecules. 2022. PMID: 36358918 Free PMC article.
Congenital hyperinsulinism.
Dillon PA. Dillon PA. Curr Opin Pediatr. 2013 Jun;25(3):357-61. doi: 10.1097/MOP.0b013e3283600ebb. Curr Opin Pediatr. 2013. PMID: 23652685 Review.
Bispecific antibodies for the treatment of breast cancer.
Dillon PM, Tushir-Singh J, Lum LG. Dillon PM, et al. Expert Opin Biol Ther. 2022 Aug;22(8):1017-1027. doi: 10.1080/14712598.2021.1922665. Epub 2021 May 9. Expert Opin Biol Ther. 2022. PMID: 33896311 Free PMC article. Review.
Paraneoplastic neurological complications of breast cancer.
Fanous I, Dillon P. Fanous I, et al. Among authors: dillon p. Exp Hematol Oncol. 2016 Oct 24;5:29. doi: 10.1186/s40164-016-0058-x. eCollection 2015. Exp Hematol Oncol. 2016. PMID: 27800287 Free PMC article. Review.
547 results